AbbVie GK, the Japanese subsidiary of AbbVie, Eisai and its subsidiary EA Pharma have received the additional approval for a new dosing regimen of Humira Pre-filled Syringe 40mg / 0.8mL for Subcutaneous Injection (adalimumab [recombinant], Humira).

Humira is a fully human, anti-TNF, monoclonal antibody formulation to be used in patients suffering from moderate to severe Crohn’s disease, and become less responsive to treatment with 40mg every two weeks to double the dose to 80mg every two weeks.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The usual adult dose of Humira used to treat Crohn’s disease includes an initial dose of 160mg of adalimumab (recombinant) administered subcutaneously (SC) followed by 80mg SC two weeks after the initial dose, and then after four weeks of the initial dose.

Eventually, 40mg SC is given every two weeks thereafter.

"Humira is a fully human, anti-TNF, monoclonal antibody formulation to be used in patients suffering from moderate to severe Crohn’s disease."

However, during the course, some patients became less responsive to their treatment, necessitating therapy aimed at ‘long-term maintenance of remission’, the aim of treatment for Crohn’s disease.

See Also:

A Japanese clinical study recently revealed the efficacy of an increased dose of 80mg every two weeks in patients who become less responsive to the traditional dose.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This resulted in an additional approval being granted for a change in dosing regimen for these patients.

AbbVie is the marketing and manufacturing authorisation holder for Humira in Japan, while the company, along with EA Pharma, is co-promoting Humira for the indications in the field of gastrointestinal diseases such as Crohn’s disease, intestinal Bechet’s disease and ulcerative colitis.

Abbvie and Eisai are co-promoting Humira for the indications in the fields other than gastrointestinal disease including plaque psoriasis, rheumatoid arthritis, ankylosing spondylitis, arthropathic psoriasis and juvenile idiopathic arthritis.